Enhancement of antiviral immunity in HBV mouse model by blocking PD-1/PD-L1 signaling pathway.
- Author:
Zhi-hong WENG
1
;
Pian YE
;
Shu-ling ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antigens, Surface; metabolism; Apoptosis Regulatory Proteins; metabolism; B7-1 Antigen; metabolism; B7-H1 Antigen; DNA, Viral; analysis; Disease Models, Animal; Hepatitis B virus; metabolism; Hepatitis B, Chronic; immunology; metabolism; virology; Male; Membrane Glycoproteins; metabolism; Mice; Mice, Inbred C57BL; Peptides; metabolism; Programmed Cell Death 1 Receptor; Signal Transduction
- From: Chinese Journal of Hepatology 2010;18(4):263-266
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo establish a mouse model for human chronic HBV infection, and to investigate the role of PD-1/PD-L1 signaling pathway in antiviral immunity.
METHODSA mouse model was established by hydrodynamic injection of the plasmid pAAV/HBV1.2-GFP into the tail vein of C57BL/6 mice, HBV markers were assayed at different time points after injection. After intraperitoneal injection of anti-PD-L1 monoclonal antibody, the serum ALT, and HBV DNA in the serum, liver and kidney were assayed.
RESULTSThe chronic HBV infection mouse model were established successfully, serum HBsAg and high load of HBV DNA were detectable 90 days after plasmid injection. After blocking of the PD-1/PD-L1 pathway, the serum ALT level of mice were significantly increased (P < 0.01), and the HBV DNA load in serum (P < 0.01), liver (P < 0.05) and kidney (P < 0.05) were decreased significantly.
CONCLUSIONBlocking the PD-1/PD-L1 signaling pathway can enhance antiviral response in mice with chronic HBV infection.
